Reasons to be very optimistic...20 Jan 2021 15:27
Let's change the tone here for all LTH's that arer feeling a little deflated. We are in the period that is expected to be, as stated by by Sir Marc Feldman, as a key inflection point in the progression of the company.
Remind yourselves of some of these incredible projects that are , in pharma terms, imminent in terms of progression and therefore crucial to achieving the inflection point!
CBR:
the Company has developed a cell therapy platform, which it is calling CBR. The essence of CBR is the programming of immune cells using a novel type of modifiable synthetic receptor to destroy viral pathogens including SARS-CoV-2 which causes COVID-19. Not only can this type of synthetic receptor potentially combat viral pathogens, it can also potentially be modified to program immune cells to destroy malignant cells causing cancer. The novel synthetic receptor has no connection to, and does not resemble, any known or widely used Chimeric Antigen Receptors (CARs, e.g., HEMO-CAR-T), and the Directors are not aware of any direct competitor for this product candidate at this time.
NO DIRECT COMPETITOR....Think about it..... and then smile.